Showing results (2501-2510 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 29, 2014
Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid BRebecca Hamm, Yoshikazu Sugimoto, Heinrich Steinmetz, et al.
Investigational New Drugs|January 1, 1985
Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in miceD S Zaharko, J M Covey
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Investigational New Drugs|August 27, 2013
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary siteAsuka Tsuya, Takayasu Kurata, Akihiro Tamiya, et al.
Investigational New Drugs|August 27, 2013
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinomaChi Hang Wong, Herbert H Loong, Connie W C Hui, et al.
Investigational New Drugs|September 10, 2013
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancerCheryl Ho, Angela M Davies, Randeep S Sangha, et al.
Investigational New Drugs|September 20, 2013
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)Godefridus J Peters, Kees Smid, Leonardo Vecchi, et al.
Investigational New Drugs|September 24, 2013
Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibitionCheree Fitzgibbon, Saleh Ihmaid, Jasim Al-Rawi, et al.
Investigational New Drugs|September 17, 2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamideChanghoon Yoo, Jeeyun Lee, Sun Young Rha, et al.
Investigational New Drugs|September 28, 2013
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignanciesS F Dent, K A Gelmon, K N Chi, et al.
Pageof 372